Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Futibatinib and Pembrolizumab in Metastatic MSS Endometrial Carcinoma
NCT05036681Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2021
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors, Reversible Covalent Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of futibatinib, pembrolizumab in endometrial carcinoma, sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2021; status: terminated.
02
Drugs
futibatinibpembrolizumab
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT05036681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05036681.